Discontinued cardiovascular drugs in 2013 and 2014

Expert Opinion on Investigational Drugs

Volumn 24, Issue 8, 2015, Pages 1083-1092

  Zhao, Hong Ping ^a   Xiang, Bing Ren ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

Dalcetrapib; DSP 9599; ISIS CRPRx; Limaprost alfadex; NTC 801; Parogrelil hydrochloride; R 118; RG 7652; RTA 402; TC 5214

Indexed keywords

BARDOXOLONE METHYL; CARDIOVASCULAR AGENT; DALCETRAPIB; DEXMECAMYLAMINE; DSP 9599; ISIS CRPRX; LIMAPROST; NTC 801; PAROGRELIL; R 118; RG 7652; UNCLASSIFIED DRUG; NEW DRUG;

ARTICLE; ASTHMA; ATHEROSCLEROSIS; ATRIAL FIBRILLATION; BUERGER DISEASE; CARDIOVASCULAR DISEASE; CARPAL TUNNEL SYNDROME; DEPRESSION; DIABETIC NEPHROPATHY; DRUG EFFICACY; DRUG MANUFACTURE; DRUG SAFETY; HEPATITIS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATORY DISEASE; INTERMITTENT CLAUDICATION; MELANOMA; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MUSCULOSKELETAL DISEASE; NEOPLASM; NONHUMAN; OVERACTIVE BLADDER; PANCREAS TUMOR; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RHEUMATOID ARTHRITIS; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; VERTEBRAL CANAL STENOSIS; ANIMAL; CARDIOVASCULAR DISEASES; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG SCREENING; TREATMENT FAILURE;

ANIMALS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUGS, INVESTIGATIONAL; HUMANS; TREATMENT FAILURE;

EID: 84949959267     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2015.1051619     Document Type: Article

References (65)

1. WHO. Cardiovascular diseases (CVDs). 2015. Available from: http://www.who. int/mediacentre/factsheets/fs317/en/[Last accessed 27 March 2015]
2. WHO. Cardiovascular disease. 2015. Available from: http://www.who. int/cardiovascular-diseases/en/[Last accessed 27 March 2015]
3. Okokok. Cardiovascular Therapeutic Drugs: Technologies and Global Markets. 2010. Available from: http://www. okokok.com.cn/Htmls/PE-Product/100805/84271.html [Last accessed 27 March 2015]
4. Mori M, Hirata T, Ikeno A, et al. DSP-9599, a novel direct renin inhibitor, reduces renal injury in double transgenic rats over-expressing both human renin and angiotensinogen genes[Adstract PP.42.353]. 23rd Eur Meet Hypertens; June 14-17, Milan
5. Ikeno A, Mori M, Kawai H, et al. A first-in-human, phase 1 study of DSP-9599, a novel direct renin inhibitor, with translational assessment in high-renin monkey[Abstract PP.20.162].23rd Eur Meet Hypertens; June 14-17, Milan) 2013
6. Dainippon Sumitomo Pharma. Supplementary Financial Data for the Year Ended March 31, 2012. 2012. Available from: http://www.dspharma. com/ir/library/financial-results-summary/pdf/ebr20120510-2.pdf [Last accessed 12 March 2015]
7. Dainippon Sumitomo Pharma. Supplementary Financial Data for the Third Quarter of the Year Ending March 31, 2013. 2013. Available from: http://www.dspharma. com/ir/library/financial-results-summary/pdf/ebr20130131-2.pdf [Last accessed 12 March 2015]
8. Jenkins Y, Sun TQ, Li Y, et al. Global metabolite profiling of mice with high-fat diet-induced obesity chronically treated with AMPK activators R118 or metformin reveals tissue-selective alterations in metabolic pathways. BMC Res Notes 2014;7:674
9. Murray O; Robinson. Parkinsons Disease Gene Networks. 2010. Available from: http://media.virbcdn.com/files/6d/78117666ecd66df9-PDGeneNetworksMolquant.pdf [Last accessed 13 March 2015]
10. PR Newswire. Rigel Announces Publication Of R118 AMPK Activator Research. 2014. Available from: http://www.thestreet.com/story/12519501/1/rigel-announces-publication-of-r118-ampk-activator-research.html [Last accessed 23 March 2015]
11. PR Newswire. R348 Did Not Meet Endpoints in Phase 2 Dry Eye Study. 2014. Available from: http://www. thestreet.com/story/12843148/1/r348-did-not-meet-endpoints-in-phase-2-dryeye-study.html [Last accessed 23 March 2015]
12. Wikipedia. Prostaglandin. 2014. Available from: http://en. wikipedia.org/wiki/Prostaglandin#cite-note-isbn0-87893-617-3-1 [Last accessed 6 March 2015]
13. ONO PHARMACEUTICAL. Announcement on Co-development and Co-marketing Agreement for Carpaltunnel Syndrome, an Additional Indication of Limaprost, an Oral Prostaglandin E1 Analogue. 2011. Available from: http://www.ono.co.jp/eng/news/pdf/sm-cn110601.pdf [Last accessed 23 March 2015]
14. Sumitomo Dainippon Pharma. Discontinuation of Development for the Additional Indication of Carpal-Tunnel Syndrome, for Limaprost, an Oral Prostaglandin E1 Analogue. 2013. Available from: http://www.dspharma. com/news/2013/20130125.html [Last accessed 6 March 2015]
15. ONO PHARMACEUTICAL. Discontinuation of Development for an Additional Indication of Cervical Spondylosis of Limaprost Alfadex, an Oral Prostaglandin E1 Derivative Preparation. 2008. Available from: http://www.dspharma. com/pdf-view.php?id=145 [Last accessed 23 March 2015]
16. Clinicaltrials.gov. The Study About the Efficacy of Oral Limaprost After Surgery for Cervical Myelopathy. 2014. Available from: https://www. clinicaltrials.gov/ct2/show/NCT02125981?term=limaprost +alfadex&rank=1 [Last accessed 6 March 2015]
17. Taisho Pharmaceuticals. Taking Resolute Steps in a Shifting Market Annual Report 2008. 2008. Available from: http://www.taishoholdings. co.jp/ir/library/pdf/annual/08-all.pdf [Last accessed 6 March 2015]
18. Brass EP, Anthony R, Cobb FR, et al. The novel phosphodiesterase inhibitor NM-702 improves claudication-limited exercise performance in patients with peripheral arterial disease. J Am Coll Cardiol 2006;48(12):2539-45
19. Ishiwata N, Noguchi K, Kawanishi M, et al. NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walkingdistance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model. Life Sci 2007;81(21):970-8
20. Clinicaltrials.gov. Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication. 2006. Available from: https://www. clinicaltrials.gov/ct2/show/NCT00102050?term=nm-702&rank=1 [Last accessed 6 March 2015]
21. Taisho Pharmaceutical Co Ltd. Second Quarter of FY2014. 2015. Available from: http://www.taishoholdings. co.jp/en/ir/library/pdf/presentation/14-1031-01-e.pdf [Last accessed 3 April 2015]
22. Taisho Pharmaceutical Co Ltd. Discontinuation of Development of NT-702 for a Part of Indications. 2009. Available from: http://www.taisho. co.jp/en/company/release/2009/2009082601-e.pdf [Last accessed 3 April 2015]
23. Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin Announces the Development Status of Bardoxolone Methyl (RTA 402) in Patients with Chronic Kidney Disease and Type 2 Diabetes in Japan. 2013. Available from: http://kyowa-kirin. com/news-releases/2013/e20131111-01. html [Last accessed 10 March 2015]
24. Kyowa Hakko Kirin Co., Ltd. Kyowa Hakko Kirin and Reata Pharmaceuticals entered into a licensing agreement on bardoxolone methyl in Japan and other selected Asian markets. 2010. Available from: http://kyowa-kirin. com/news-releases/2010/e20100108-01. html [Last accessed 10 March 2015]
25. Kyowa Hakko Kirin Co., Ltd. Future development direction for bardoxolone methyl (RTA 402). 2014. Available from: http://kyowa-kirin. com/news-releases/2014/e20140702-01. html [Last accessed 10 March 2015]
26. Hong DS, Kurzrock R, Supko JG, et al. A Phase I. First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas. Clin Cancer Res 2012;18(12):3396-406
27. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323(18):1234-8
28. Roche. Roche provides update on Phase III study of dalcetrapib. 2012. Available from: http://www.roche.com/media/store/releases/med-cor-2012-05-07. htm [Last accessed 10 March 2015]
29. Schwartz GG, Olsson AG, Abt M, et al. dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367(22):2089-99
30. Japan Tobacco. JTs Consolidated Financial Results for the 12 months ended March 31, 2012. 2012. Available from: http://www.jti.com/files/5413/3542/0077/FINAL-JTs-Consolidated-Financial-Results-for-the-12-months-ended-March-31-2012.pdf [Last accessed 10 March 2015]
31. Tokyo. JTs consolidated financial results for FY2013 first quarter. 2013. Available from: http://www.jt.com/media/press-releases/2013/pdf/20130730-02.pdf [Last accessed 23 March 2015]
32. Lippiello PM, Beaver JS, Gatto GJ, et al. TC-5214 (S-(+)-mecamylamine): a neuronal nicotinic receptor modulator with antidepressant activity. CNS Neurosci Ther 2008;14(4):266-77
33. Targacept, Inc. Targacept announces plans to develop enantiomer of mecamylamine as augmentation therapy for depression. 2007. Available from: http://www. medicalnewstoday.com/releases/86693. php [Last accessed 10 May 2015]
34. Fedorov N, Moore L, Gatto G, et al. Differential effects of TC-5214[S-(+)-mecamylamine]and TC-5213[R-(-)-mecamylamine] at low and high sensitivity human alpha4beta2 nicotinic receptors and in animal models of depression and anxiety. TC 2007;100:150
35. AstraZeneca. A Study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. 2010. Available from: https://www. clinicaltrials.gov/ct2/show/NCT01197508? term=NCT01197508&rank=1 [Last accessed 23 March 2015]
36. AstraZeneca. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. 2010. Available from: https://www. clinicaltrials.gov/ct2/show/NCT01180400? term=NCT01180400&rank=1 [Last accessed 23 March 2015]
37. AstraZeneca. A study to assess the longterm safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. 2010. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01152554? term=NCT01152554&rank=1 [Last accessed 23 March 2015]
38. AstraZeneca. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder. 2010. Available from: https://www.clinicaltrials. gov/ct2/show/NCT01153347? term=NCT01153347&rank=1 [Last accessed 23 March 2015]
39. AstraZeneca. A study to assess the efficacy and safety of TC-5214 as an adjunct therapy in patients with major depressive disorder (MDD). 2010. Available from: https://www. clinicaltrials.gov/ct2/show/NCT01157078? term=NCT01157078&rank=1 [Last accessed 23 March 2015]
40. Press Release. AstraZeneca and targacept announce remaining TC-5214 phase 3 efficacy studies do not meet primary endpoint, regulatory filing will not be pursued. 2012. Available from: http://www.targacept.com/newsroom/index.cfm?nid=AstraZeneca%20and% 20Targacept%20Announce% 20Remaining%20TC%2D5214% 20Phase%203%20Efficacy%20Studies% 20Do%20Not%20Meet%20Primary% 20Endpoint%2C%20Regulatory% 20Filing%20Will%20Not%20Be% 20Pursued&newsyear=2012 [Last accessed 23 March 2015]
41. Press Release. Targacept announces plans to develop TC-5214 in overactive bladder. 2012. Available from: http://www.targacept.com/newsroom/index.cfm?nid=Targacept%20Announces %20Plans%20to%20Develop%20TC% 2D5214%20in%20Overactive% 20Bladder&newsyear=2012 [Last accessed 23 March 2015]
42. Press Release. Targacept announces initiation of phase 2b study of TC-5214 in overactive bladder. 2013. Available from: http://www.targacept. com/newsroom/index.cfm?nid=Targacept %20Announces%20Initiation%20of% 20Phase%202b%20Study%20of%20TC %2D5214%20in%20Overactive% 20Bladder&newsyear=2013 [Last accessed 23 March 2015]
43. Press Release. Targacept to discontinue TC-5214 overactive bladder program. 2014. Available from: http://www. targacept.com/newsroom/index.cfm? nid=Targacept%20to%20Discontinue% 20TC%2D5214%20Overactive% 20Bladder%20Program&newsyear=2014 [Last accessed 23 March 2015]
44. Press Release. Targacept reports second quarter 2009 financial results. 2009. Available from: http://www. targacept.com/newsroom/index.cfm? nid=Targacept%20Reports%20Second% 20Quarter%202009%20Financial% 20Results&newsyear=2009 [Last accessed 23 March 2015]
45. Teijin. Consolidated financial statements summary. 2009. Available from: http://www.teijin. com/ir/library/consolidated-results/pdf/cr-091102.pdf [Last accessed 23 March 2015]
46. John Carroll. BMS offers up to 385M to develop atrial fibrillation drug. 2009. Available from: http://www. fiercebiotech.com/story/bms-offers-385mdevelop-atrial-fibrillation-drug/2009-03-05 [Last accessed 11 March 2015]
47. Nissan Chemical Industries, Ltd. Annual report 201011. Available from: http://www.nissanchem.co.jp/ir-info/archive/ar/ar2010.pdf [Last accessed 11 March 2015]
48. John Carroll. Isis dumps rheumatoid arthritis effort after antisense drug flunks PhII. 2013. Available from: http://www.fiercebiotech.com/story/isisdumps-rheumatoid-arthritis-effort-afterantisense-drug-flunks-phii/2013-08-05 [Last accessed 12 March 2015]
49. Roche. Media release. 2012. Available from: http://www.roche. com/media/store/releases/med-cor-2012-09-05.htm [Last accessed 13 March 2015]
50. ClinicalTrials. A phase II study of the safety and efficacy of MPSK3169A in patients with coronary heart disease or high risk of coronary heart disease. 2012. Available from: https://www. clinicaltrials.gov/ct2/show/NCT01609140? term=NCT01609140&rank=1 [Last accessed 13 March 2015]
51. Roche. Pipeline summary. 2014. Available from: http://www.roche. com/irp2q14e-annex.pdf [Last accessed 13 March 2015]
52. Zhang XS, Xiang BR. Discontinued drugs in 2007: cardiovascular drugs. Expert Opin Investig Drugs 2008;17(12):1817-28
53. Zhang XS, Xiang BR. Discontinued drugs in 2008: cardiovascular drugs. Expert Opin Investig Drugs 2009;18(7):875-85
54. Zhao HP, Zhang XS, Xiang BR. Discontinued drugs in 2010: cardiovascular drugs. Expert Opin Investig Drugs 2010;20(10):1311-25
55. Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2012: cardiovascular drugs. Expert Opin Investig Drugs 2013;22(11):1437-51
56. Zhao HP, Jiang HM, Xiang BR. Discontinued drugs in 2011: cardiovascular drugs. Expert Opin Investig Drugs 2012;21(10):1449-62
57. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-16
58. AIM-HIGH Investigators. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365(24):2255-67
59. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122(8):850-2
60. Vogel RA. PCSK9 inhibition: the next statin? J Am Coll Cardiol 2012;59(25):2354-5
61. Sanofi. Sanofi and regeneron present detailed positive results from four pivotal alirocumab trials at ESC Congress. 2014. Available from: http://en.sanofi. com/Images/37129-20140831- AlirocumabESCDataRelease-en.pdf [Last accessed 28 March 2015]
62. AMGEN. Amgen announces positive top-line results from phase 3 TESLA trial of evolocumab (AMG 145) in patients with homozygous familial hypercholesterolemia. 2014. Available from: https://www. clinicaltrials.gov/ct2/show/NCT01609140? term=NCT01609140&rank=1 [Last accessed 28 March 2015]
63. Randi Hernandez. Amgen Sues sanofi and regeneron over patent for mAb targeting PCSK9. 2014. Available from: http://www. biopharminternational.com/amgen-suessanofi-and-regeneron-over-patent-mabtargeting-pcsk9 [Last accessed 28 March 2015]
64. Sanofi. Sanofi and Regeneron Announce Praluent (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA. 2015. Available from: http://en.sanofi. com/Images/38242-20150226-alirocumabbla-en.pdf [Last accessed 28 March 2015]
65. AMGEN. Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha (evolocumab) In Japan. 2015. Available from: http://wwwext. amgen.com/media/media-pr-detail.jsp?year=2015&releaseID=2027353 [Last accessed 28 March 2015]